Patient-reported outcomes in ovarian cancer clinical trials

Annals of Oncology

Volumn 24, Issue SUPPL.10, 2013, Pages

  Friedlander, M L ^a   King, M T ^b  

^a Australia and New Zealand Gynaecology Oncology Group   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

HRQOL; Ovarian cancer; Patient reported outcomes

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; PLATINUM DERIVATIVE;

ARTICLE; CANCER RECURRENCE; CLINICAL TRIAL; FEMALE; HEALTH STATUS; HUMAN; OVARY CANCER; PANCREAS CANCER; PREVALENCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PSYCHOMETRY; QUALITY OF LIFE; RELIABILITY; SOCIAL STATUS; SYMPTOMATOLOGY; TREATMENT OUTCOME; VALIDITY;

HRQOL; OVARIAN CANCER; PATIENT-REPORTED OUTCOMES;

CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; OVARIAN NEOPLASMS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84888265677     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt474     Document Type: Article

References (28)

1. United States Food and Drug Administration. Guidance for Industry Patient- Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Rockville, MD: United States Food and Drug Administration, 2006.
2. Lyman GH, Levine M. Comparative effectiveness research in oncology: an overview. J Clin Oncol 2012; 30: 4181-4184.
3. EMEA. Committee for Medicinal Products for Human Use (CMHP) Doc Ref EMEA/CHMP/EWP/139391/2004. London: European Medicines Agency; 2005. Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products.
4. McKenna S. Measuring patient reported outcomes: moving beyond misplaced common sense to hard science. BMC Med 2011; 9: 86 1-12.
5. Agarwal S, Bodurka DC. Symptom research in gynecologic oncology: a review of available measurement tools. Gynecol Oncol 2010; 119: 384-389.
6. Ganz P, Gotay CC. Use of patient reported outcomes in phase 3cancer treatment trials: lessons learned and future directions. J Clin Oncol 2007; 25: 5063-5069.
7. Rothman ML, Beltran P, Cappelleri JC et al. Mayo/FDA Patient-Reported Outcomes Consensus Meeting Group Patient-reported outcomes: conceptual issues. Value Health 2007; 10(Suppl 2): S66-S75.
8. Luckett T, King MT. Choosing patient-reported outcome measures for cancer clinical research-practical principles and an algorithm to assist non-specialist researchers. Eur J Cancer 2010; 46: 3149-3157.
9. Brundage M, Bass B, Davidson J et al. Patterns of reporting health-related quality of life outcomes in randomized clinical trials: implications for clinicians and quality of life researchers. Qual Life Res 2011; 20(5): 653-664.
10. Calvert M, Blazeby J, Altman DA et al., for the CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA 2013; 309(8): 814-822.
11. Ferrans CE. Definitions and conceptual models of quality of life. In J Lipscomb CCG, Snyder C (eds), Outcome Research in Cancer: Measures Methods and Applications. Cambridge, UK: Cambridge University Press 2005: 14-30.
12. Effectiveness Guidance Document. Recommendations for incorporating Patient Reported Outcomes(PRO's) into Clinical Comparative Effectiveness Research(CER) in Adult Oncology Published Version 1.0 May 2012. www.cmptnet.org.
13. Luckett T, King MT, Butow PN et al. Heading G Choosing between the EORTC QLQ-C30 and FACT-G for measuring health-related quality of life in cancer clinical research: issues, evidence and recommendations. Ann Oncol (IF 5.647) 2011; 22 (10): 2179-2190.
14. Cella DF, Tulsky DS, Gray G et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993; 11: 570-579.
15. Cella D, Paul D, Yount S et al. What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Invest 2003; 21(4); 526-535.
16. Beaumont S, Yount D, Lalla D et al. Validation of the Functional Assessment of Cancer Therapy-Ovarian (FACT-O) Symptom Index (FOSI) in a phase II clinical trial of pertuzumab in patients with advanced ovarian cancer. J Clin Oncol ASCO Annual Meeting Proceedings Part I 2007; 25(18S); 16021.
17. Jensen SE, Rosenbloom SK, Beaumont JL et al. A new index of priority symptoms in advanced ovarian cancer. Gynecol Oncol 2011; 120(2): 214-219.
18. Basen-Engquist K, Bodurka-Bevers D, Fitzgerald MA et al. Reliability and validity of the functional assessment of cancer therapy-ovarian. J Clin Oncol 2001; 19: 1809-1817.
19. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85(5): 365-376.
20. Greimel E, Bottomley A, Cull A et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. Eur J Cancer 2003; 39: 1402-1408.
21. Brundage M, Gropp M, Mefti F et al. Health-related quality of life in recurrent platinum-sensitive ovarian cancer-results from the CALYPSO trial. Ann Oncol 2012; 23: 2020-2027.
22. du Bois A, Quinn M, Thigden T et al. 2004 Consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 2005; 16: 7-12.
23. Stuart GC, Kitchener H, Bacon M et al. Gynecologic cancer intergroup 2010 gynecologic cancer interGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the fourth ovarian cancer consensus conference. Int J Gynecol Cancer 2011; 21(4): 750-755.
24. Basch E, Abernethy AP, Mullins CD et al. Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol 2012; 30(34): 4249-4255.
25. Bell ML, Fairclough DL. Practical and statistical issues in missing data for longitudinal patientreported outcomes. Stat Methods Med Res 2013; February 19 [epub ahead of print], doi:10.1177/0962280213476378.
26. Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F et al. Impact of FOLFIRINOX compared With gemcitabine on quality of life in patients With metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol 2013; 31(1): 23-29.
27. Matsuda A, Yamaoka K, Tango T. Quality of life in advanced non-small cell lung cancer patients receiving palliative chemotherapy: a meta-analysis of randomized controlled trials. Exp Ther Med 2012; 3(1): 134-140.
28. Calvert M, Blazeby J, Revicki D et al. Reporting quality of life in clinical trials: a CONSORT extension. Lancet 2011; 378(9804): 1684-1685.